Safety and Dose Finding Study of Xigris (Drotrecogin Alfa Activated) as an Anti-coagulant in End Stage Renal Disease (ESRD) Patients Treated With Hemodialysis (HD).

Trial Profile

Safety and Dose Finding Study of Xigris (Drotrecogin Alfa Activated) as an Anti-coagulant in End Stage Renal Disease (ESRD) Patients Treated With Hemodialysis (HD).

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jan 2014

At a glance

  • Drugs Drotrecogin alfa (Primary)
  • Indications Thrombosis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 28 Jun 2011 Actual end date (Dec 2010) as reported by ClinicalTrials.gov.
    • 28 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Oct 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top